Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression

@article{Campo2011CharacterizationOA,
  title={Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression},
  author={Brice Campo and Mikhail Kalinichev and Nathalie Lambeng and Malika El Yacoubi and Isabelle Royer-Urios and Manfred Schneider and Coline Legrand and Delphine Parron and Françoise Girard and Abdelhak Bessif and Sonia Maria Poli and J. M. Vaugeois and Emmanuel Le Poul and Sylvain Celanire},
  journal={Journal of Neurogenetics},
  year={2011},
  volume={25},
  pages={152 - 166}
}
There is growing evidence suggesting that antagonists of group II metabotropic glutamate receptors (mGluR2/3) exhibit antidepressant-like properties in several preclinical models of depression. [...] Key Result In vitro, RO4491533 completely blocked the glutamate-induced Ca(2+) mobilization and the glutamate-induced accumulation in [(35)S]GTP(γS) binding in cells expressing recombinant human or rat mGluR2 and in native tissues.Expand
ADX71743, a Potent and Selective Negative Allosteric Modulator of Metabotropic Glutamate Receptor 7: In Vitro and In Vivo Characterization
TLDR
In vivo tests using ADX71743 suggest that pharmacological inhibition of mGlu7 is a valid approach for developing novel pharmacotherapies to treat anxiety disorders, but may not be suitable for treatment of depression or psychosis. Expand
Characterization of the Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 ADX88178 in Rodent Models of Neuropsychiatric Disorders
TLDR
The pharmacological evaluation of ADX88178 shows good specificity as it had no effect on locomotor activity in mice and rats at efficacious doses, and can be a promising new therapeutic approach for treatment of anxiety, OCD, fear-related disorders, and psychosis. Expand
Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.
TLDR
The behavioral experiments presented here with compound 106 represent the first examples in which an mGlu3 NAM has demonstrated efficacy in models where prior efficacy had previously been noted with nonselective group II antagonists. Expand
mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants
TLDR
Preclinical and clinical evidence of mGLU2/3 receptor ligands and mGlu5 receptor antagonists and their potential in clinic will be discussed in the context of neuronal mechanisms of ketamine, an agent recently demonstrated a robust effect for patients with treatment-resistant depression. Expand
Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators
TLDR
A novel mGlu2 positive allosteric modulator (PAM) radioligand is developed and characterized and it is found that PAMs affect both the affinity and efficacy of glutamate at mGLU2, whereas NAMs predominantly affect the efficacy of MSG in the assay system. Expand
Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2.
TLDR
The design and synthesis of a radiolabeled negative allosteric modulator (NAM) for mGlu2 PET tracer development based on a quinoline 2-carboxamide scaffold is reported, and [11C]QCA is a chemical probe that provides the basis for the development of a new generation mGLU2PET tracers. Expand
mGlu2/3 receptor antagonists.
  • S. Chaki
  • Medicine
  • Advances in pharmacology
  • 2019
TLDR
This chapter focuses on the usefulness of mGlu2/3 receptor antagonists as novel antidepressants, in comparison with ketamine, and their therapeutic potential. Expand
mGlu2/3 Receptor Antagonists as Novel Antidepressants.
  • S. Chaki
  • Medicine
  • Trends in pharmacological sciences
  • 2017
TLDR
The potential for mGlu2/3 receptor antagonists to be developed as next-generation antidepressants is discussed. Expand
mGlu receptors as potential targets for novel antidepressants
TLDR
The synaptic and neural mechanisms underlying the antidepressant actions of mGLU2/3 receptor and mGlu5 receptor antagonists have been elucidated, in comparison with those of ketamine. Expand
Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer mouse
TLDR
Assessment of the therapeutic potential of chronic pharmacological inhibition of Group II mGluR in Dutch APP transgenic mice found it to offer a unique package of relevant properties as an Alzheimer’s disease therapeutic or prophylactic by providing both attenuation of neuropathology and stimulation of repair. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
Context-Dependent Pharmacology Exhibited by Negative Allosteric Modulators of Metabotropic Glutamate Receptor 7
TLDR
It is described that MMPIP acts as a noncompetitive antagonist in calcium mobilization assays in cells coexpressing mGluR7 and the promiscuous G protein Gα15, and the pharmacology of this compound represents a striking example of the potential for context-dependent blockade of receptor responses by negative allosteric modulators. Expand
MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity
TLDR
The results indicate that MGS0039 is a potent and selective antagonist of group II mGluR, and that group IImGLUR antagonists, like M GS0039, have an antidepressant-like potential in experimental animal models. Expand
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
TLDR
It is concluded that behavioral profile of mGlu2/3 receptor antagonists as represented by LY-341495 is different from that of conventional anxiolytic and antidepressant drugs. Expand
An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats
TLDR
Additional evidence is provided that MGS0039 exhibits antidepressant and anxiolytic effects in experimental rodent models, which are predictive of clinical efficacy and suggest that the blockade of mGluR2/3 with M GS0039 may be effective in the treatment of depressive and anxiety disorders. Expand
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors
TLDR
The in vitro pharmacology of a structurally novel compound, LY341495, was investigated at human recombinant metabotropic glutamate (mGlu) receptor subtypes expressed in non-neuronal cells and represents a novel pharmacological agent for elucidating the function of mGlu receptors in experimental systems. Expand
AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist
TLDR
Findings suggest that stimulation of postsynaptic AMPA receptors plays a role in mediating the pharmacological effects of MGS0039, a selective group II metabotropic glutamate receptor (mGluR) antagonist that exhibits antidepressant-like activities in rodent models. Expand
[3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain.
TLDR
These studies indicate that [3H]LY341495 selectively labels group II (mGlu2/3) receptors, but under the conditions used, it may bind predominately to mGlu3 receptor populations in the rat forebrain. Expand
Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons
TLDR
It is speculated that selective mGlu3 receptor agonists or enhancers are potential candidates as neuroprotective agents in Parkinson's disease, and their use might circumvent the limitations associated with the administration of exogenous GDNF. Expand
Glutamate and depression: clinical and preclinical studies.
TLDR
Recent data indicate that a single intravenous dose of an NMDA receptor antagonist is sufficient to produce sustained relief from depressive symptoms, and these findings represent exciting and novel avenues to both understand depressive symptomatology and develop more effective antidepressants. Expand
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia
TLDR
The discovery of a small molecule modulator, LY2033298, that is highly selective for human M4 receptors by virtue of targeting an allosteric site on this receptor is described, indicating its potential use as a first-in-class, selective,allosteric muscarinic antipsychotic agent. Expand
...
1
2
3
4
5
...